Hepatitis A and B vaccine

The hepatitis A and B vaccine is a combined immunization designed to provide protection against two viral liver infections: hepatitis A and hepatitis B. It is administered by intramuscular injection, generally into the deltoid muscle. Combining the two vaccines allows a person who needs protection against both diseases to receive them through one coordinated product rather than through separate hepatitis A and hepatitis B vaccination courses. The vaccine is used in settings where hepatitis A and hepatitis B are endemic, and it is commonly considered for travelers, people with hepatitis C or chronic liver disease, and people whose circumstances place them at increased risk of sexually transmitted infections. Its use reflects the overlapping populations that may benefit from protection against both viruses, while also offering a more convenient vaccination pathway than administering the component vaccines independently. The best-known commercial formulation is Twinrix, manufactured by GlaxoSmithKline Biologicals. The product combines the technology and antigen components associated with Havrix, an inactivated hepatitis A vaccine, and Engerix-B, a recombinant hepatitis B vaccine. Twinrix entered the market in early 1997. Depending on the market and age group, related names include Twinrix Adult, Twinrix Junior, Twinrix Paediatric, Ambirix, and Bilive. A routine Twinrix schedule consists of three intramuscular doses given at months 0, 1, and 6. Minimum intervals are used when the schedule must be adjusted: at least four weeks between the first and second doses and at least five months between the second and third doses. An accelerated schedule can also be used in some circumstances, with doses at day 0, day 7, and day 21 to 30, followed by a booster at 12 months. The accelerated regimen has been reported to produce efficacy comparable to the conventional schedule when used appropriately. Clinical-trial results summarized by the U.S. Centers for Disease Control and Prevention indicate that protection against hepatitis A one month after the first, second, and third doses was approximately 93.8%, 98.8%, and 99.9%, respectively. Corresponding protection against hepatitis B was approximately 30.8%, 78.2%, and 98.5%. These figures illustrate the progressive immune response associated with completing the series, particularly for hepatitis B. The combined vaccine has generally been described as well tolerated, with a safety profile comparable to that of the separate hepatitis A and hepatitis B vaccines. Common reactions include temporary pain, redness, or a small lump at the injection site, as well as headache, tiredness, or faintness. Other reported reactions include rash, bruising, numbness, tingling, muscle weakness, pain, and unusual bleeding such as nose or gum bleeding. Serious reactions, including allergic responses and seizures, are rare. As with other vaccines, product labeling and local immunization guidance determine appropriate use, schedules, age indications, and precautions. The product is widely available, although formulations and licensing differ by jurisdiction. In the United States, Twinrix is approved by the Food and Drug Administration for adults aged 18 and older. Canada and countries in the European Union use market-specific names and also make pediatric formulations available in some settings. Beyond its clinical role, the combination may reduce administrative effort and help improve uptake by consolidating vaccination against two infections into a coordinated course.

The hepatitis A and B vaccine emerged from the practical need to immunize individuals against two distinct viral hepatitis infections through a coordinated product. Hepatitis A is associated with an inactivated-virus vaccine approach, while hepatitis B protection in the combined product is based on recombinant vaccine technology. The commercial combination brings together the antigenic components associated with Havrix and Engerix-B, two established hepatitis vaccines manufactured by GlaxoSmithKline Biologicals. The principal branded product, Twinrix, entered the market in early 1997. Its development and commercialization created a single vaccination option for people who might otherwise have needed separate hepatitis A and hepatitis B courses. This was particularly relevant for international travelers and for people living or working in areas where both infections are endemic. The combination also offered a way to coordinate vaccination for individuals with chronic liver disease, hepatitis C, or circumstances associated with increased risk of sexually transmitted infections. Twinrix is administered intramuscularly, normally in the deltoid region. The standard course uses three doses at 0, 1, and 6 months. The minimum intervals between doses are four weeks between the first and second doses and five months between the second and third doses. An accelerated program can be used in some circumstances, consisting of injections on day 0, day 7, and day 21 to 30, followed by a booster at 12 months. The accelerated schedule was reported to produce efficacy similar to the conventional regimen when used according to applicable guidance. Evidence summarized by the U.S. Centers for Disease Control and Prevention describes a strong cumulative immune response. One month after the first, second, and third doses, reported protection against hepatitis A was 93.8%, 98.8%, and 99.9%; the corresponding hepatitis B figures were 30.8%, 78.2%, and 98.5%. These results support the importance of completing the vaccination series, especially for hepatitis B protection. The product’s safety profile has been characterized as comparable to that of separate hepatitis A and hepatitis B vaccines. Most reactions are mild and temporary, particularly injection-site pain, redness, or a small lump. Headache, tiredness, faintness, and other less common symptoms may occur. Rare serious events include allergic reactions and seizures. Product labeling, age indications, contraindications, and scheduling rules vary by jurisdiction. The vaccine has been marketed under several names. In the United States, Twinrix is approved for adults aged 18 and older. In Canada and the European Union, the product may be identified as Twinrix Adult or Ambirix, while pediatric versions have been marketed as Twinrix Junior or Twinrix Paediatric. Bilive is another listed brand name. The continued availability of multiple formulations reflects adaptation to local regulatory systems and age-specific vaccination needs. As a combination product, it may also lower administrative burdens and encourage uptake by simplifying the process of receiving protection against both infections.

1. 1997Twinrix enters the market

   Twinrix, a combined hepatitis A and hepatitis B vaccine manufactured by GlaxoSmithKline Biologicals, entered the market in early 1997.

   Source

A convenient combination vaccine for people requiring protection against both hepatitis A and hepatitis B, including travelers and groups with elevated exposure or liver-disease risk.

• Combined hepatitis A and B vaccineCombination vaccine

  The generic vaccine category combines protection against hepatitis A and hepatitis B in a single injectable product. It is administered intramuscularly and is used for people who require protection against both infections. Depending on the jurisdiction and formulation, vaccination may follow a conventional three-dose course or an accelerated schedule with a later booster.

• TwinrixAdult combination vaccine1997

  Twinrix is the principal commercial brand associated with the combined hepatitis A and B vaccine. It uses the inactivated hepatitis A and recombinant hepatitis B components associated with Havrix and Engerix-B. The routine course consists of three intramuscular doses at 0, 1, and 6 months, with an accelerated option available in some circumstances.

• Twinrix JuniorPediatric combination vaccine

  Twinrix Junior is a pediatric market formulation of the combined hepatitis A and B vaccine. Availability and age indications depend on local authorization and product labeling.

• Twinrix PaediatricPediatric combination vaccine

  Twinrix Paediatric is a pediatric formulation marketed in some jurisdictions for combined hepatitis A and hepatitis B immunization. Its approved age range and schedule are determined by the relevant national regulator.

• AmbirixCombination vaccine

  Ambirix is a market-specific brand name for a combined hepatitis A and hepatitis B vaccine. It is associated with availability in markets outside the United States, including parts of the European Union.

• BiliveCombination vaccine

  Bilive is another listed brand name for a combined hepatitis A and hepatitis B vaccine. Public reference material identifies it as a market-specific name rather than as a separate vaccine category.

1. Hepatitis A and B vaccine